11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Files in this item

This item appears in the following Collection(s)

Search DSpace



Browse

My Account

Statistics